Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    51,403.59
    +1,070.12 (+2.13%)
     

  • CMC Crypto 200

    1,367.25
    +54.63 (+4.16%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

FDA staff question utility of Novo Nordisk combo diabetes drug

Reuters - UK Focus

May 20 (Reuters) - A preliminary review by the U.S (Other OTC: UBGXF - news) . Food and Drug Administration of Novo Nordisk A/S (LSE: 0QIU.L - news) 's experimental diabetes drug, IDegLira, questioned the interpretability of the study findings and practical utility of the treatment, according to a review posted on the agency's website on Friday.

The review comes ahead of a May 24 meeting of an FDA advisory panel that will meet to discuss the drug and make recommendations as to whether it should be approved. The FDA is not obliged to follow the advice of its advisory panels but typically does so. (Reporting by Toni Clarke in Washington)